Next-Generation Antibody-Drug Conjugates (ADCs)

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 243

Special Issue Editor


E-Mail Website
Guest Editor
Texas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, TMC3 Collaborative Building, 7255 Helix Park Avenue, Houston, TX 77030, USA
Interests: medicinal chemistry; targeted therapy; drug delivery; antibody-drug conjugate; structural molecular biology; nuclear receptor superfamily; cancer; immune disease

Special Issue Information

Dear Colleagues,

I am pleased to invite you to contribute to the Special Issue entitled “Next-Generation Antibody–Drug Conjugates”.

ADCs are an emerging drug class for cancer treatment, with 11 successful FDA-approved ADCs for many indications, including both hematological malignancies and solid tumors. Recent advances, including antibody formats (such as a bispecific antibody), conjugation chemistry, linker technology and novel payloads beyond cytotoxic molecules (such as an immunomodulator), can move ADCs to the next generation.

This Special Issue aims to provide cutting-edge knowledge in the field of ADCs. Original research articles and reviews are welcome. Research topics may include the following (but are not limited to): novel antigens, antibodies including fragments and other formats (e.g., bispecific), conjugation methods, linkers and payloads for ADCs. Papers reporting on basic to translational/(pre)clinical research are welcome. Other submissions that facilitate the development of ADCs are also welcome.

I look forward to receiving your contributions.

Dr. Yasuaki Anami
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • antibody–drug conjugate
  • bioconjugation
  • vancer therapy
  • targeted therapy
  • bystander effect

Published Papers

This special issue is now open for submission.
Back to TopTop